BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models

International Journal of Cancer

Volumn 140, Issue 2, 2017, Pages 449-459

  Politz, Oliver ^a   Siegel, Franziska ^a   Bärfacker, Lars ^a   Bömer, Ulf ^a   Hägebarth, Andrea ^a   Scott, William J ^b   Michels, Martin ^a   Ince, Stuart ^b   Neuhaus, Roland ^a   Meyer, Kirstin ^a   Fernández Montalván, Amaury Ernesto ^a   Liu, Ningshu ^a   von Nussbaum, Franz ^a   Mumberg, Dominik ^a   Ziegelbauer, Karl ^a  

^a BAYER AG   (Germany)

^b Bayer HealthCare Pharmaceuticals Inc   (United States)

Author keywords

AKT; breast cancer; kinase inhibitor; patient derived models; prostate cancer

Indexed keywords

AKT1 PROTEIN; ANDROGEN RECEPTOR; BAY 1125976; ESTROGEN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN KINASE B INHIBITOR; UNCLASSIFIED DRUG; 3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; AKT1 PROTEIN, MOUSE; AKT2 PROTEIN, MOUSE; NITRILE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; SULFONE; TARGET OF RAPAMYCIN KINASE;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANUS CANCER; ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; CACO-2 CELL LINE; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; HELA CELL LINE; MCF-7 CELL LINE; METABOLISM; NUDE MOUSE; PHOSPHORYLATION; PROCEDURES; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CACO-2 CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; HELA CELLS; HUMANS; MALE; MCF-7 CELLS; MICE; MICE, NUDE; MICE, SCID; NITRILES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SULFONES; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84995495504     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30457     Document Type: Article

References (43)

1. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261–74.
2. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606–19.
3. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274–93.
4. Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988–1004.
5. Karni R, de Stanchina E, Lowe SW, et al. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007;14:185–93.
6. Kumar R, Hung MC. Signaling intricacies take center stage in cancer cells. Cancer Res 2005;65:2511–5.
7. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075–83.
8. McCubrey JA, Abrams SL, Stadelman K, et al. Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. Adv Enzyme Regul 2010;50:285–307.
9. Mosca E, Barcella M, Alfieri R, et al. Systems biology of the metabolic network regulated by the Akt pathway. Biotechnol Adv 2012;30:131–41.
10. Wu WI, Voegtli WC, Sturgis HL, et al. Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. PLoS One 2010;5:e12913
11. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005;9:59–71.
12. Calleja V, Laguerre M, Parker PJ, et al. Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol 2009;7:e17
13. Cho H, Mu J, Kim JK, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001;292:1728–31.
14. Altomare DA, Lyons GE, Mitsuuchi Y, et al. Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin. Oncogene 1998;16:2407–11.
15. Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Mol Biosyst 2015;11:1946–54.
16. Bertrand FE, McCubrey JA, Angus CW, et al. NOTCH and PTEN in prostate cancer. Adv Biol Regul 2014;56:51–65.
17. Georgescu MM. PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer 2010;1:1170–7.
18. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439–44.
19. Marco CD, Malanga D, Rinaldo N, et al. Mutant AKT1-E17K is oncogenic in lung epithelial cells. Oncotarget 2015;6:39634–50.
20. Parikh C, Janakiraman V, Wu W-I, et al. Disruption of PH–kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc Natl Acad Sci 2012;109:19368–73.
21. Kolasa IK, Rembiszewska A, Felisiak A, et al. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biology & Therapy 2009; 8:21–6.
22. Coffey JC, Wang JH, Smith MJ, et al. Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. Novel role for an old enemy. J Biol Chem 2005;280:20968–77.
23. Pal SK, Reckamp K, Yu H, et al. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2010;19:1355–66.
24. Ruiter GA, Zerp SF, Bartelink H, et al. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 2003;14:167–73.
25. Dumble M, Crouthamel MC, Zhang SY, et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PloS One 2014;9:e100880
26. Lin J, Sampath D, Nannini MA, et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res 2013;19:1760–72.
27. Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 2012;11:873–87.
28. Hyman DM, Smyth L, Bedard, PL, et al. AZD5363, a catalytic pan-AKT inhibitor, in AKT1 E17K mutation positive advanced solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2015.
29. She QB, Halilovic E, Ye Q, et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010;18:39–51.
30. Stein U, Walther W, Stege A, et al. Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA. Mol Ther 2008;16:178–86.
31. Klein KA, Reiter RE, Redula J, et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997;3:402–8.
32. Kurebayashi J, Otsuki T, Tang CK, et al. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br J Cancer 1999;79:707–17.
33. Barnett SF, Defeo-Jones D, Fu S, et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 2005;385:399–408.
34. Liu N, Rowley BR, Bull CO, et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110alpha and p110delta activities in tumor cell lines and xenograft models. Mol Cancer Ther 2013;12:2319–30.
35. Andre F, Bachelot T, Campone M, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res 2013;19:3693–702.
36. Bleeker FE, Felicioni L, Buttitta F, et al. AKT1(E17K) in human solid tumours. Oncogene 2008;27:5648–50.
37. Dillon RL, Marcotte R, Hennessy BT, et al. Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res 2009;69:5057–64.
38. Meng Q, Xia C, Fang J, et al. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal 2006;18:2262–71.
39. Saji M, Narahara K, McCarty SK, et al. Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer. Oncogene 2011;30:4307–15.
40. Virtakoivu R, Pellinen T, Rantala JK, et al. Distinct roles of AKT isoforms in regulating beta1-integrin activity, migration, and invasion in prostate cancer. Mol Biol Cell 2012;23:3357–69.
41. Yun J. Allosteric AKT inhibitors as a targeted cancer therapy. Cancer Biol Ther 2010;9:504–6.
42. Lindsley CW, Barnett SF, Layton ME, et al. The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Curr Cancer Drug Targets 2008;8:7–18.
43. Maynard J, Ricketts SA, Gendrin C, et al. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363. Mol Imaging Biol 2013;15:476–85.